tetano
Editor, Senior Moderator
Pediatrics
. 2023 Aug 3;e2023061297.
doi: 10.1542/peds.2023-061297. Online ahead of print. Early Treatment of Multisystem Inflammatory Syndrome in Children
Brian Jonat[SUP] #[/SUP][SUP] 1 [/SUP], Andrew S Geneslaw[SUP] #[/SUP][SUP] 1 [/SUP], Christine A Capone[SUP] 2 [/SUP], Sareen Shah[SUP] 2 [/SUP], Lisa Bartucca[SUP] 3 [/SUP], Taylor B Sewell[SUP] 1 [/SUP], Karen P Acker[SUP] 3 [/SUP], Elizabeth Mitchell[SUP] 2 [/SUP], Eva W Cheung[SUP] 1 [/SUP]
Affiliations
Background and objectives: Multisystem inflammatory syndrome in children (MIS-C) is a severe hyperinflammatory illness occurring after severe acute respiratory syndrome coronavirus 2 infection. The optimal treatment of MIS-C is unknown, although prior studies have indicated benefits of intravenous immunoglobulin (IVIG) and glucocorticoids. We hypothesize that early treatment with glucocorticoids is associated with shorter hospital length of stay (LOS).
Methods: This study is a multicenter retrospective cohort study of patients hospitalized with MIS-C over a roughly 1-year period. The primary outcome was hospital LOS comparing subjects who received glucocorticoids within 48 hours of arrival to the treating hospital to those who did not. Secondary outcomes included ICU LOS. Unadjusted and adjusted analyses were performed.
Results: The final analysis included 131 subjects. Subjects who received early glucocorticoids were more likely to receive early IVIG and to require ICU admission. Early glucocorticoid administration was associated with shorter ICU LOS (4 vs 9 days, P = .004) in the unadjusted analysis. In the adjusted analysis, early glucocorticoid administration and early IVIG administration were both independently associated with shorter hospital LOS (incidence rate ratio 0.75, P = .025; incidence rate ratio 0.56, P = .026, respectively).
Conclusions: Glucocorticoids and intravenous immunoglobulin were independently associated with shorter hospital length of stay when given early in hospitalization to MIS-C patients after accounting for potential confounding factors. The optimal dose and duration of treatment require further investigation, but this study supports early combination therapy with both IVIG and glucocorticoids for all children hospitalized with MIS-C.
. 2023 Aug 3;e2023061297.
doi: 10.1542/peds.2023-061297. Online ahead of print. Early Treatment of Multisystem Inflammatory Syndrome in Children
Brian Jonat[SUP] #[/SUP][SUP] 1 [/SUP], Andrew S Geneslaw[SUP] #[/SUP][SUP] 1 [/SUP], Christine A Capone[SUP] 2 [/SUP], Sareen Shah[SUP] 2 [/SUP], Lisa Bartucca[SUP] 3 [/SUP], Taylor B Sewell[SUP] 1 [/SUP], Karen P Acker[SUP] 3 [/SUP], Elizabeth Mitchell[SUP] 2 [/SUP], Eva W Cheung[SUP] 1 [/SUP]
Affiliations
- PMID: 37534417
- DOI: 10.1542/peds.2023-061297
Background and objectives: Multisystem inflammatory syndrome in children (MIS-C) is a severe hyperinflammatory illness occurring after severe acute respiratory syndrome coronavirus 2 infection. The optimal treatment of MIS-C is unknown, although prior studies have indicated benefits of intravenous immunoglobulin (IVIG) and glucocorticoids. We hypothesize that early treatment with glucocorticoids is associated with shorter hospital length of stay (LOS).
Methods: This study is a multicenter retrospective cohort study of patients hospitalized with MIS-C over a roughly 1-year period. The primary outcome was hospital LOS comparing subjects who received glucocorticoids within 48 hours of arrival to the treating hospital to those who did not. Secondary outcomes included ICU LOS. Unadjusted and adjusted analyses were performed.
Results: The final analysis included 131 subjects. Subjects who received early glucocorticoids were more likely to receive early IVIG and to require ICU admission. Early glucocorticoid administration was associated with shorter ICU LOS (4 vs 9 days, P = .004) in the unadjusted analysis. In the adjusted analysis, early glucocorticoid administration and early IVIG administration were both independently associated with shorter hospital LOS (incidence rate ratio 0.75, P = .025; incidence rate ratio 0.56, P = .026, respectively).
Conclusions: Glucocorticoids and intravenous immunoglobulin were independently associated with shorter hospital length of stay when given early in hospitalization to MIS-C patients after accounting for potential confounding factors. The optimal dose and duration of treatment require further investigation, but this study supports early combination therapy with both IVIG and glucocorticoids for all children hospitalized with MIS-C.